Trials / Active Not Recruiting
Active Not RecruitingNCT04208347
Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer
Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Resectable Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma: A Multicenter, Randomized Phase II-III Trial
- Status
- Active Not Recruiting
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 580 (estimated)
- Sponsor
- Ruijin Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The study is being conducted to evaluate the efficacy, safety and tolerability of chemotherapy and apatinib with or without camrelizumab in the neoadjuvant (prior to surgery) or adjuvant (after surgery) treatment of previously untreated adults with gastric and gastroesophageal junction (GEJ) adenocarcinoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Apatinib 250mg | Apatinib 250mg |
| DRUG | Camrelizumab | Camrelizumab 200mg |
| DRUG | S-1, Oxaliplatin | S-1, Oxaliplatin, q3w |
| DRUG | Apatinib 500mg | Apatinib 500mg |
Timeline
- Start date
- 2019-12-18
- Primary completion
- 2026-12-01
- Completion
- 2027-12-01
- First posted
- 2019-12-23
- Last updated
- 2026-01-23
Locations
23 sites across 1 country: China
Source: ClinicalTrials.gov record NCT04208347. Inclusion in this directory is not an endorsement.